Delcath Systems Inc., a development-stage specialty pharmaceutical and medical device company focused on oncology, today announced that the first patients in Europe have been treated with the Delcath Hepatic CHEMOSAT® Delivery System at the European Institute of Oncology (BATS:IEO), a premier cancer treatment and research center in Milan.
CHEMOSAT is a proprietary product that utilizes a minimally invasive, repeatable procedure to deliver high doses of chemotherapeutic drugs directly to the liver while minimizing systemic exposure of such drugs.
The two patients were treated for inoperable liver-dominant metastases from ocular melanoma and gastric cancer. Delcath reports that the procedures were successfully completed without procedure-related complications.
"The CHEMOSAT system represents an important advancement in treatment options for cancers in the liver, which have significantly poorer survival rates compared to cancers that have spread predominantly to other organs," Dr. Alessandro Testori, a surgical oncologist and director of the Division of Melanoma and Skin-Muscle Sarcoma at the IEO stated in the press release. "We believe this technology will help fill an important gap in the treatment of multiple tumor types in the liver because of its demonstrated ability to deliver concentrated doses of chemotherapeutic agent directly to the liver while helping to minimize systemic exposure. We are pleased to be the first center in Europe to begin offering this treatment to patients and look forward to exploring its potential with Delcath."
The procedures were conducted with the Generation One version of the CHEMOSAT system, which received CE Mark approval in April 2011; the Generation Two version is under review for CE Mark approval.
"Since obtaining our CE Mark, Delcath has been committed to supporting the technology in the substantial international liver cancer market," said Eamonn P. Hobbs, president and CEO of Delcath. "These cases represent the first uses of CHEMOSAT outside of a clinical trial-an exciting milestone for Delcath. There is no greater endorsement for CHEMOSAT than to have the first European patients treated at an organization as prestigious as the IEO. We are delighted that the procedures were successfully performed, and look forward to continued collaborative progress with the IEO and the opportunity to open additional CHEMOSAT treatment centers across Europe."
Delcath and the IEO will host a joint-press conference, on February 15, 2012, at the IEO, and give an update on patient status.
For more information visit www.delcath.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html